ReviewLife (Basel, Switzerland)2022
Thyroid Eye Disease.
Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Evaluation of parafoveal region and foveal avascular zone in inactive Grave's ophthalmopathy using optical coherence tomography angiography: a meta-analysis.BMC ophthalmology · 2025Pooled it
- Optical coherence tomography angiography in thyroid associated ophthalmopathy: a systematic review.BMC ophthalmology · 2024Pooled it
- Review
- Article
- IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease.Scientific reports · 2026Review
- Hypoxia-Induced Ferroptosis Resistance Drives Orbital Fibrosis in Thyroid Eye Disease.Investigative ophthalmology & visual science · 2026Article
- The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease.Reviews in endocrine & metabolic disorders · 2026Review
- [From dry skin to myxedema: the skin as a mirror of thyroid function].Dermatologie (Heidelberg, Germany) · 2026Review
- Teprotumumab for Thyroid Eye Disease: Mechanism, Clinical Efficacy, and Current Challenges.Antibodies (Basel, Switzerland) · 2025Review
- Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database.Clinical endocrinology · 2025Article
- Development and validation of potential molecular subtypes and signatures of thyroid eye disease based on angiogenesis-related gene analysis.BMC pharmacology & toxicology · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- Autoimmune Thyroid Disease and Pregnancy: The Interaction Between Genetics, Epigenetics and Environmental Factors.Journal of clinical medicine · 2024Review
- Article
- A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Hyperlipidemia and apolipoprotein E are associated with intraocular pressure of thyroid-associated ophthalmopathy in a Chinese population: a cross-sectional study.Frontiers in endocrinology · 2024Article
- Purine metabolism-related genes and immunization in thyroid eye disease were validated using bioinformatics and machine learning.Scientific reports · 2023Article
- Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review.Cureus · 2023Review
- Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema.AACE endocrinology and diabetesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid eye disease (TED), an autoimmune inflammatory disorder of the orbit, presents with a potential array of clinical sequelae. The pathophysiology behind TED has been partially characterized in the literature. There remain certain elusive mechanisms welcoming of research advances. Disease presentation can vary, but those that follow a characteristic course start mild and increase in severity before plateauing into an inactive phase. Diagnosis and evaluation include careful physical examination, targeted laboratory work up, appropriate imaging studies, and tailored treatment regimens. Special consideration may apply to certain populations, such as pediatric and pregnant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.